NEPH

Nephros has crossed from a perennial cash-burner into a genuinely profitable business, and the market hasn't fully repriced it. FY2025 revenue grew 32.7% to $18.8M with a 61.9% gross margin, while net income swung to $1.19M (from $74K) and operating cash flow more than quintupled to $1.65M. Crucially, the growth is structural, not a one-off: management attributes it to sales-team expansion in both 2024 and 2025, and the core 'programmatic' revenue is recurring filter replacement tied to clinical and operational workflows. All medical filters are FDA 510(k)-cleared Class II devices — a real moat in critical-use water safety. At $3.40 the stock trades at just 1.9x sales and 30.9x earnings; the P/E looks full only because net margin is a thin 6.4%, which is precisely the operating-leverage setup — incremental revenue on a 62% gross margin should flow disproportionately to the bottom line.

The balance sheet removes the classic microcap failure mode. Equity is $10.2M against only $3.44M of liabilities (0.34x), cash rose 43.6% to $5.40M, and there is essentially no debt. With positive operating cash flow, Nephros is no longer dependent on the dilutive capital raises its risk factors warn about — shares outstanding grew just 0.4%. ROE is a respectable 11.7% and improving as the newly-profitable earnings base compounds against a stable share count.